|
|
| Considering outsourcing development and manufacturing? The Outsourced Pharma Capacity Update (OPCU), a free, interactive, digital event, convenes the industry's foremost CDMOs to provide up-to-date and direct insights into their available capacity and services, alongside specific facility and equipment updates. Discover the July 2025 event’s presenting sponsors in this newsletter to learn how they are best suited to help you to navigate the path to approval and commercialization. |
|
|
SMALL MOLECULE API & HPAPI DEVELOPMENT |
|
|
Aragen | Explore specialized expertise in solving challenging small molecule formulation problems (poor solubility, bioavailability, complex delivery routes). | Request Information | Aragen |
|
|
MilliporeSigma | Applications specialist John Stevens shows how MilliporeSigma is using their 35+ years of CDMO experience and expertise to move small molecules forward to the clinic and to commercialization. | Request Information | MilliporeSigma |
|
|
|
Lonza | ASDs are an attractive option for progressing and commercializing poorly soluble compounds. Find capabilities to screen the potential for ASDs in early phase studies and their commercial applicability. | Request Information | Lonza |
|
|
|
MilliporeSigma | With more than 15 years of experience as conjugation and linker-payload CDMO, MilliporeSigma has a proven track record of supporting clinical programs from IND to PPQ for commercialization. | Request Information | MilliporeSigma |
|
|
Lonza | Leveraging Lonza's deep ADC expertise and experience, successfully develop high quality, commercially viable processes, spanning from pre-clinical development through commercial scale manufacturing. | Request Information | Lonza |
|
|
Simtra BioPharma Solutions | With more than 65 years of sterile injectable manufacturing experience, Simtra offers world-class GMP sterile fill/finish services, deep scientific and technical expertise, and a uniquely collaborative approach. | Request Information | Simtra BioPharma Solutions |
|
|
SMALL MOLECULE FINISHED DOSAGE FORM |
|
|
Quotient Sciences | Compressed timelines pose challenges, ranging from limited API supply to clinical trial logistics. Expedited review pathways can be used to accelerate development while mitigating CMC risks. | Request Information | Quotient Sciences |
|
|
Douglas CDMO | Lora Wallis and Chris Cuthbertson highlight Douglas CDMO’s strengths in high-potency softgels and liquids and the company's 67 years of expertise and a client-centric approach. | Request Information | Douglas CDMO |
|
|
PCI Pharma Services | Dr. Rebecca Coutts highlights PCI’s high potent oral solid dose (OSD) and oral liquid capabilities, focusing on site expertise, specialized infrastructure, and handling of complex molecules. | Request Information | PCI Pharma Services |
|
|
Upperton Pharma Solutions | Ian Lafferty, CTO, and Josh Moule, Business Development Manager, talk through Upperton’s capabilities and project management approach. See a virtual tour of their development and manufacturing facility. | Request Information | Upperton Pharma Solutions |
|
|
Bora Pharmaceuticals | Bora Pharmaceuticals specializes in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, and sterile injectable products. | Request Information | Bora Pharmaceuticals |
|
|
|
|